Lead Product(s) : Carotegrast Methyl
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : EA Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Primary endpoint was achieved in Phase III clinical study (AJM300/CT3) of AJM300 (nonproprietary name: carotegrast methyl), which EA Pharma and Kissei Pharmaceutical have developed for treatment of ulcerative colitis.
Brand Name : AJM300
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 13, 2021
Lead Product(s) : Carotegrast Methyl
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : EA Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
